Royalty Report: Drugs, Cancer, Therapeutic – Collection: 239975

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Cancer
  • Therapeutic
  • Genome
  • Viral Infection

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 239975

License Grant
Licensor hereby grants to the Swiss Licensee an exclusive right and license in the Option Territory under the Licensor Technology to develop, manufacture, have manufactured, export, import, market, use, offer to sell, sell and register, and otherwise exploit, the Option Product in the Field.
License Property
Licensor received exclusive worldwide rights to the oncolytic virus therapy products and related intellectual property.

An oncolytic virus is a virus that preferentially infects and kills cancer cells. As the infected cancer cells are destroyed by oncolysis, they release new infectious virus particles or virions to help destroy the remaining tumour.

Field of Use
The agreement is for the development and commercialization of oncolytic virus therapies.

IPSCIO Record ID: 230782

License Grant
With this agreement, Licensee shall, at Licensors request, assign to Licensor all right, title and interest in and to such Licensee Patent, and, in return

The Swiss Licensor shall grant to Licensee a non-exclusive, limited license back under such Licensee Patent to the extent necessary for Licensee to perform its obligations under this Development License and Commercialization Agreement and the associated Manufacturing and Supply Agreement.

License Property
Licensee received exclusive worldwide rights to the oncolytic virus therapy products and related intellectual property.
Field of Use
The agreement is for the development and commercialization of oncolytic virus therapies.  Licensee has focused its research and product development efforts on human disease therapies that are based on innovative gene modification technologies.

An oncolytic virus is a virus that preferentially infects and kills cancer cells. As the infected cancer cells are destroyed by oncolysis, they release new infectious virus particles or virions to help destroy the remaining tumour.

IPSCIO Record ID: 155866

License Grant
Licensor grants an exclusive sublicense under the acquired University Patents relating to lometrexol granted in December 1985, and an exclusive license under the Licensor Patents to make, have made, use, sell, offer to sell and import the Product in the Territory.
License Property
The product is a finished pharmaceutical composition containing the compound lometrexol.

Lometrexol is an oncolytic agent in the therapeutic class known as antifolates.

Field of Use
An oncolytic virus is a virus that preferentially infects and kills cancer cells.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.